<DOC>
	<DOCNO>NCT00618540</DOCNO>
	<brief_summary>RATIONALE : Giving monoclonal antibody , alemtuzumab , chemotherapy drug , fludarabine melphalan , donor stem cell transplant help stop patient 's immune system reject donor 's stem cell help stop growth abnormal cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well give alemtuzumab together fludarabine melphalan follow donor stem cell transplant work treat young patient resistant Langerhans cell histiocytosis .</brief_summary>
	<brief_title>Reduced Intensity Hematopoietic Cell Transplantation Patients With Resistant Langerhans Cell Histiocytosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine overall disease-free survival poor-risk pediatric patient Langerhans cell histiocytosis 1 3 year reduced-intensity hematopoietic cell transplantation ( RI-HCT ) . Secondary - To determine day 100 transplantation-related mortality . - To determine incidence hematopoietic recovery chimerism day 100 1 year post RI-HCT . - To determine incidence grade II-IV III-IV acute graft-versus-host disease ( GVHD ) . - To determine incidence chronic GVHD . OUTLINE : This multicenter study . - Non-myeloablative conditioning : Patients receive alemtuzumab intravenously ( IV ) 2 hour day -8 -4 , fludarabine phosphate IV 30-60 minute day -7 -3 , melphalan IV 15-30 minute day -2 . Some patient may receive anti-thymocyte globulin IV day -6 -2 instead alemtuzumab . - Graft-versus-host disease prophylaxis immunosuppression : Patients receive cyclosporine A ( CSA ) IV orally 2-3 time daily begin day -3 continue day 50 post transplantation , follow taper 8 week absence GVHD donor lymphocyte infusion give decrease donor chimerism . Patients mismatch donor ( source ) receive peripheral blood stem cell also receive mycophenolate mofetil ( MMF ) IV orally 2-3 time daily begin day -3 continue day 30 7 day engraftment , whichever day later , absence GVHD . In patient acute GVHD require systemic therapy , Mycophenolate mofetil ( MMF ) may stop 7 day initiation systemic therapy . - Allogeneic hematopoietic stem cell infusion : Patients undergo infusion bone marrow ( prefer ) peripheral blood stem cell day 0 . Patients also receive filgrastim ( G-CSF ) subcutaneously IV begin day 8 continue blood count recover 2 consecutive day . - Donor lymphocyte infusion ( DLI ) : Patients mixed chimerism ( i.e. , &lt; 95 % donor ) &lt; 50 % donor T-cell engraftment engraftment assessment time point eligible DLI , absence GVHD . If mixed chimerism persists , escalate dos CD3-positive lymphocyte administer every 3-4 week , absence GVHD . After completion study therapy , patient follow engraftment day 100 , 6 month , 1 year , annually thereafter 2-5 year .</detailed_description>
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Histiocytosis , Langerhans-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Histologically confirm Langerhans cell histiocytosis ( LCH ) demonstration CD1a positivity Birbeck granules lesion Considered poorrisk , define multisystem disease involvement one risk organ ( i.e. , liver , spleen , lung , and/or hematopoietic system ) No isolated `` lung '' LCH Progressive disease one follow treatment : LCHIII protocol standard LCHdirected therapy At least 1 course current salvage protocol ( i.e. , LCH2 2005 ) similar therapy ( e.g. , cytosine arabinoside cladribinebased regimen ) HLAmatched relate unrelated donor OR unrelated umbilical cord blood ( UCB ) available 1 locus mismatch donor allow Up 2 locus mismatch unrelated UCB allow Any hematologic status ( transfusion support allow ) Adequate hepatic , renal , cardiac , pulmonary function undergo reducedintensity hematopoietic cell transplantation ( RIHCT ) include follow : Transaminases &lt; 5 time upper limit normal ( ULN ) Bilirubin &lt; 3 time ULN ( unless secondary hepatic LCH ) Creatinine ≤ 2 mg/dL ( adult ) ( creatinine &gt; 1.2 OR history renal dysfunction , must estimate creatinine clearance &gt; 40 mL/min ) Creatinine clearance &gt; 40 mL/min ( pediatrics ) Glomerular filtration rate ≥ 50mL/min Negative pregnancy test Decompensated congestive heart failure , uncontrolled arrhythmia , leave ventricular ejection fraction ≥ 35 % Pulmonary failure ( i.e. , require mechanical ventilation ) unless secondary active underlie LCH Isolated liver sclerosis pulmonary fibrosis unless secondary active underlie LCH Uncontrolled active lifethreatening infection Pregnant nursing Less 4 week last attempted salvage chemotherapy treatment Other concurrent chemotherapy agent ( e.g. , methotrexate ) entire transplantation period day 100 posttransplantation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>childhood Langerhans cell histiocytosis</keyword>
</DOC>